4.6 Article

Therapeutic options in treatment-resistant depression

期刊

ANNALS OF MEDICINE
卷 43, 期 7, 页码 512-530

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/07853890.2011.583675

关键词

Depression; resistance; treatment

资金

  1. Spanish Ministry of Health, Instituto de Salud Carlos III, CIBER-SAM
  2. Spanish Ministry of Science and Innovation, Instituto Carlos III, through a 'Miguel Servet' [CP08/00140]
  3. FIS [PS09/01044]
  4. Almirall
  5. AstraZeneca
  6. Bristol-Myers Squibb
  7. Eli Lilly
  8. Forest Research Institute
  9. Geodon Richter
  10. GlaxoSmithKline
  11. Janssen-Cilag
  12. Jazz
  13. Lundbeck
  14. Merck
  15. Novartis
  16. Organon
  17. Otsuka
  18. Pfizer Inc.
  19. Sanofi aventis
  20. Servier
  21. Solvay
  22. Schering-Plough
  23. Takeda
  24. United Biosource Corporation
  25. Wyeth
  26. Spanish Ministry of Science and Innovation
  27. Stanley Medical Research Institute
  28. European Union
  29. Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III

向作者/读者索取更多资源

The phenomenon of treatment-resistant depression (TRD), described as the occurrence of an inadequate response after an adequate treatment with antidepressant agents (in terms of dose, duration, and adherence), is very common in clinical practice. It has been broadly defined in the context of unipolar major depression, but alternative definitions for bipolar depression have also been suggested. In both cases, there is a remarkable lack of consensus amongst professionals concerning its operative definition. A relatively wide variety of treatment options for unipolar TRD are available, whilst the evidence is very scanty for bipolar TRD. TRD is associated to poor clinical, functional, and social outcomes. Several novel therapeutic options are currently being investigated as promising alternatives, targeting the neurotransmitter system outside of the standard monoamine hypothesis. Augmentation or combination with lithium or atypical antipsychotics appears as a valid option for both conditions, and the same occurs with electroconvulsive therapy. Other non-pharmacological strategies such as deep brain stimulation may be promising alternatives for the future. The use of cognitive behaviour therapy is recommended for unipolar TRD, but there is no evidence supporting its use in bipolar TRD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据